129 related articles for article (PubMed ID: 26679149)
21. Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach.
Tan GS; McKenna PM; Koser ML; McLinden R; Kim JH; McGettigan JP; Schnell MJ
Virology; 2005 Jan; 331(1):82-93. PubMed ID: 15582655
[TBL] [Abstract][Full Text] [Related]
22. Intranasal vaccination with a helper-dependent adenoviral vector enhances transgene-specific immune responses in BALB/c mice.
Fu YH; He JS; Zheng XX; Wang XB; Xie C; Shi CX; Zhang M; Tang Q; Wei W; Qu JG; Hong T
Biochem Biophys Res Commun; 2010 Jan; 391(1):857-61. PubMed ID: 19945423
[TBL] [Abstract][Full Text] [Related]
23. Heterologous HIV-based lentiviral/adenoviral vectors immunizations result in enhanced HIV-specific immunity.
Asefa B; Korokhov N; Lemiale F
Vaccine; 2010 Apr; 28(20):3617-24. PubMed ID: 20051277
[TBL] [Abstract][Full Text] [Related]
24. Construction and characterization of a recombinant human adenovirus type 3 vector containing two foreign neutralizing epitopes in hexon.
Xue C; Tian X; Li X; Zhou Z; Su X; Zhou R
Virus Res; 2014 Apr; 183():67-74. PubMed ID: 24518297
[TBL] [Abstract][Full Text] [Related]
25. Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B.
Yu S; Feng X; Shu T; Matano T; Hasegawa M; Wang X; Ma H; Li H; Li Z; Zeng Y
Vaccine; 2008 Nov; 26(48):6124-31. PubMed ID: 18812199
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice.
Ophorst OJ; Radosević K; Havenga MJ; Pau MG; Holterman L; Berkhout B; Goudsmit J; Tsuji M
Infect Immun; 2006 Jan; 74(1):313-20. PubMed ID: 16368986
[TBL] [Abstract][Full Text] [Related]
27. Prime-boost immunization using alphavirus replicon and adenovirus vectored vaccines induces enhanced immune responses against classical swine fever virus in mice.
Zhao HP; Sun JF; Li N; Sun Y; Wang Y; Qiu HJ
Vet Immunol Immunopathol; 2009 Oct; 131(3-4):158-66. PubMed ID: 19411115
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of a prime-boost vaccine schedule with distinct adenovirus vectors against malaria in rhesus monkeys.
Rodríguez A; Mintardjo R; Tax D; Gillissen G; Custers J; Pau MG; Klap J; Santra S; Balachandran H; Letvin NL; Goudsmit J; Radosević K
Vaccine; 2009 Oct; 27(44):6226-33. PubMed ID: 19686691
[TBL] [Abstract][Full Text] [Related]
29. Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier.
Xiang ZQ; Gao GP; Reyes-Sandoval A; Li Y; Wilson JM; Ertl HC
J Virol; 2003 Oct; 77(20):10780-9. PubMed ID: 14512528
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of a self-inactivating lentiviral vector expressing simian immunodeficiency virus gag for induction of specific immune responses in vitro and in vivo.
Buffa V; Negri DR; Leone P; Borghi M; Bona R; Michelini Z; Compagnoni D; Sgadari C; Ensoli B; Cara A
Viral Immunol; 2006; 19(4):690-701. PubMed ID: 17201664
[TBL] [Abstract][Full Text] [Related]
31. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity.
Dicks MD; Spencer AJ; Edwards NJ; Wadell G; Bojang K; Gilbert SC; Hill AV; Cottingham MG
PLoS One; 2012; 7(7):e40385. PubMed ID: 22808149
[TBL] [Abstract][Full Text] [Related]
32. Immunogenicity and protective efficacy of heterologous prime-boost regimens with mycobacterial vaccines and recombinant adenovirus- and poxvirus-vectored vaccines against murine tuberculosis.
You Q; Wu Y; Wu Y; Wei W; Wang C; Jiang D; Yu X; Zhang X; Wang Y; Tang Z; Jiang C; Kong W
Int J Infect Dis; 2012 Nov; 16(11):e816-25. PubMed ID: 22921259
[TBL] [Abstract][Full Text] [Related]
33. Immunological insights from genetic vaccines.
Ertl HC
Virus Res; 2005 Jul; 111(1):89-92. PubMed ID: 15896407
[TBL] [Abstract][Full Text] [Related]
34. Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees.
Natuk RJ; Lubeck MD; Chanda PK; Chengalvala M; Wade MS; Murthy SC; Wilhelm J; Vernon SK; Dheer SK; Mizutani S
AIDS Res Hum Retroviruses; 1993 May; 9(5):395-404. PubMed ID: 8318268
[TBL] [Abstract][Full Text] [Related]
35. A prime-boost vaccination strategy using attenuated Salmonella typhimurium and a replication-deficient recombinant adenovirus vector elicits protective immunity against human respiratory syncytial virus.
Fu YH; He JS; Wang XB; Zheng XX; Wu Q; Xie C; Zhang M; Wei W; Tang Q; Song JD; Qu JG; Hong T
Biochem Biophys Res Commun; 2010 Apr; 395(1):87-92. PubMed ID: 20350532
[TBL] [Abstract][Full Text] [Related]
36. Protective Efficacy in Sheep of Adenovirus-Vectored Vaccines against Bluetongue Virus Is Associated with Specific T Cell Responses.
Martín V; Pascual E; Avia M; Peña L; Valcárcel F; Sevilla N
PLoS One; 2015; 10(11):e0143273. PubMed ID: 26619062
[TBL] [Abstract][Full Text] [Related]
37. Optimized adenovirus-antibody complexes stimulate strong cellular and humoral immune responses against an encoded antigen in naive mice and those with preexisting immunity.
Choi JH; Dekker J; Schafer SC; John J; Whitfill CE; Petty CS; Haddad EE; Croyle MA
Clin Vaccine Immunol; 2012 Jan; 19(1):84-95. PubMed ID: 22089246
[TBL] [Abstract][Full Text] [Related]
38. Adenovirus type 4 and 7 vaccination or adenovirus type 4 respiratory infection elicits minimal cross-reactive antibody responses to nonhuman adenovirus vaccine vectors.
Paris R; Kuschner RA; Binn L; Thomas SJ; Colloca S; Nicosia A; Cortese R; Bailer RT; Sullivan N; Koup RA
Clin Vaccine Immunol; 2014 May; 21(5):783-6. PubMed ID: 24623627
[TBL] [Abstract][Full Text] [Related]
39. Effects of shielding adenoviral vectors with polyethylene glycol on vector-specific and vaccine-mediated immune responses.
Weaver EA; Barry MA
Hum Gene Ther; 2008 Dec; 19(12):1369-82. PubMed ID: 18778197
[TBL] [Abstract][Full Text] [Related]
40. Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines.
Coughlan L
Front Immunol; 2020; 11():909. PubMed ID: 32508823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
